Article thumbnail

Catechol-O-Methyltransferase (COMT) gene polymorphism and breast cancer risk in young women

By M Bergman-Jungeström and S Wingren


Oestrogen exposure has long been considered to be a main risk factor of breast cancer. More recently, interest has also focused on the possible carcinogenic influence from oestrogen metabolites, such as catechol oestrogens. O-methylation, catalysed by Catechol-O-Methyltransferase (COMT), is one pathway by which the potentially carcinogenic catechol oestrogens can be inactivated. The gene coding for COMT protein contains a single-nucleotide polymorphism (SNP), resulting in an amino acid shift Val→Met, which has been shown to determine high- and low-activity configuration of the enzyme. We hypothesized that the low-activity allele, COMTMet, may be implicated in early onset breast cancer. In the present case–control study, including 126 young breast cancer patients (≤ 36 years) and 117 healthy female blood donors, we analysed the association between COMTMet genotype and risk of breast cancer. No significant difference in the frequency of low-/high-activity alleles was found between cases and controls, indicating that the polymorphism, as a single factor, may not contribute to breast carcinogenesis in young women. © 2001 Cancer Research Campaign

Topics: Regular Article
Publisher: Nature Publishing Group
OAI identifier:
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles


  1. (1981). Aromatization of androstenedione by human adipose tissue stromal cells in monolayer culture.
  2. (1993). Relationship between the GSTM1 genetic polymorphism and susceptibility to bladder, breast and colon cancer.
  3. (1994). The endogenous oestrogen metabolite 2-methoxyoetradiol inhibits angiogenesis and suppresses tumour growth.